Endpoints News

@endpts

The biopharma world is here. Get the industry’s most comprehensive daily news reports at http://endpts.com/subscribe

following
followers

Technology

Anthropic opens partial Mythos access to approved life sciences teams

Endpoints News reports that the verification program follows Anthropic’s July 2026 ban on life sciences work using Mythos.

1 Source, 32d ago, first seen 32d ago

Technology

Novo partners with Anthropic to test Claude Science in drug discovery

Endpoints News reports that the partnership comes months after Novo signed a similar deal with OpenAI.

1 Source, 34d ago, first seen 34d ago

Technology

Contineum and J&J's PIPE-307 reportedly misses Phase 2 depression trial goal

Endpoints News reports that the drug recorded its second mid-stage miss of 2026. The outlet also reports that Contineum shares fell about 6% in premarket trading.

1 Source, 35d ago, first seen 35d ago

Technology

GSK reportedly strikes up to $750M deal for Chimagen’s T-cell engager

Endpoints News reports that the agreement covers a trispecific T-cell engager for multiple myeloma and marks GSK’s second deal with the Chinese biotech.

1 Source, 36d ago, first seen 36d ago

Technology

Anthropic is hiring a biopharma dealmaker, Endpoints News reports

Endpoints News says the corporate development role pays up to $600,000 and involves sourcing acquisitions and partnerships in life sciences.

1 Source, 42d ago, first seen 42d ago

Technology

Typewriter Therapeutics Raises $56 Million Series A

Company emerges from stealth to advance in vivo CAR T medicines.

2 Sources, 48d ago, first seen 48d ago

Featured in

Anthropic opens partial Mythos access to approved life sciences teams

Novo partners with Anthropic to test Claude Science in drug discovery

Contineum and J&J's PIPE-307 reportedly misses Phase 2 depression trial goal

GSK reportedly strikes up to $750M deal for Chimagen’s T-cell engager

Anthropic is hiring a biopharma dealmaker, Endpoints News reports

Typewriter Therapeutics Raises $56 Million Series A

Featured in

Anthropic opens partial Mythos access to approved life sciences teams

Novo partners with Anthropic to test Claude Science in drug discovery

Contineum and J&J's PIPE-307 reportedly misses Phase 2 depression trial goal

GSK reportedly strikes up to $750M deal for Chimagen’s T-cell engager

Anthropic is hiring a biopharma dealmaker, Endpoints News reports

Typewriter Therapeutics Raises $56 Million Series A